Rongtai health(SH:603579)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥564,797,326.35, representing an increase of 8.55% compared to the same period last year[5]. - The net profit attributable to shareholders decreased by 15.02% to ¥58,326,127.42[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 30.38% to ¥42,769,318.58, primarily due to a decline in gross margin[8]. - Net profit for Q1 2022 was ¥58,563,444.46, a decrease of 15.2% from ¥69,039,012.93 in Q1 2021[18]. - Total comprehensive income for Q1 2022 was CNY 58,341,010.73, a decrease from CNY 69,014,207.63 in Q1 2021[19]. - Basic earnings per share for Q1 2022 was CNY 0.44, down from CNY 0.50 in Q1 2021[19]. - The basic earnings per share for the period was ¥0.44, down by 12.00%[5]. - The diluted earnings per share was ¥0.42, a decrease of 12.50%[5]. - The weighted average return on equity was 3.23%, a decrease of 0.83 percentage points[5]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥27,415,890.24, a decrease of 146.53% compared to the previous year, mainly due to increased payments for purchased goods[8]. - Net cash flow from operating activities for Q1 2022 was negative CNY 27,415,890.24, compared to positive CNY 58,917,339.02 in Q1 2021[22]. - Cash inflow from operating activities totaled CNY 630,228,464.99 in Q1 2022, down from CNY 678,974,675.65 in Q1 2021[21]. - Cash outflow from operating activities increased to CNY 657,644,355.23 in Q1 2022, compared to CNY 620,057,336.63 in Q1 2021[22]. - Net cash flow from investing activities was CNY 70,058,635.23 in Q1 2022, a significant improvement from negative CNY 181,340,777.02 in Q1 2021[22]. - Cash inflow from financing activities was CNY 134,720,427.86 in Q1 2022, with net cash flow from financing activities of CNY 133,206,273.40[22]. - Cash and cash equivalents increased to ¥1,284,376,555.91 from ¥1,109,244,715.14 at the end of 2021, reflecting a growth of 15.8%[14]. - Cash and cash equivalents at the end of Q1 2022 were CNY 1,284,376,555.91, up from CNY 760,845,363.07 at the end of Q1 2021[22]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,370,609,904.10, an increase of 2.83% from the end of the previous year[6]. - The company's total assets as of March 31, 2022, amounted to ¥3,370,609,904.10, an increase from ¥3,277,932,920.71 at the end of 2021[14]. - Current assets totaled ¥2,131,739,325.31, slightly up from ¥2,038,261,461.70 at the end of 2021[14]. - Total liabilities increased to ¥1,528,376,484.16 from ¥1,497,786,372.69 at the end of 2021, marking a rise of 2.7%[15]. - The equity attributable to shareholders increased by 3.48% to ¥1,838,231,565.13[6]. - The equity attributable to shareholders rose to ¥1,838,231,565.13 from ¥1,776,370,370.24 at the end of 2021, an increase of 3.5%[15]. Shareholder Information - The company had a total of 9,277 common shareholders at the end of the reporting period[10]. Research and Development - The company reported a decrease in research and development expenses to ¥25,166,930.13 from ¥26,331,939.12 in Q1 2021, a decline of 4.4%[18]. Financial Expenses - The company’s financial expenses included interest expenses of ¥8,056,346.77, up from ¥7,034,346.26 in Q1 2021[18].